Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

Synthetic Blood International, Inc. (OTCBB:SYBD) announced positive data from a statistical analysis of its Phase IIa study with Oxycyte(TM) in patients with traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met. Data also show a decrease in patient glucose and lactate/pyruvate (LP) ratio, consistent with increased glucose metabolism. Patients in this trial were stabilized with either 50% or 100% oxygen. Data determined that results of both treatment arms were favorable, with statistically significant differences in some...

Want to see the full article?

• Purchase this article for only $3.00